What are the dosing recommendations for Wilate (plasma‑derived factor VIII/von Willebrand factor concentrate) in adults with hemophilia A or von Willebrand disease for acute bleeding and peri‑operative management?

Wilate Dosing for Hemophilia A and von Willebrand Disease

For von Willebrand disease, use Wilate at 20-40 IU/kg loading dose for minor hemorrhages and 40-60 IU/kg for major hemorrhages, followed by maintenance doses of 20-30 IU/kg every 12-24 hours (targeting VWF:RCo >30%) or 20-40 IU/kg every 12-24 hours (targeting VWF:RCo >50%), respectively. 1

Acute Bleeding Management in von Willebrand Disease

The FDA-approved dosing for Wilate is structured around bleeding severity:

Minor Hemorrhages

• Loading dose: 20-40 IU VWF:RCo/kg
• Maintenance: 20-30 IU/kg every 12-24 hours
• Target levels: VWF:RCo and FVIII activity trough >30%
• Duration: Up to 3 days (except GI bleeds) 1

Major Hemorrhages

• Loading dose: 40-60 IU VWF:RCo/kg
• Maintenance: 20-40 IU/kg every 12-24 hours
• Target levels: VWF:RCo and FVIII activity trough >50%
• Duration: 5-7 days (except GI bleeds which may require longer) 1

Special Considerations by Bleeding Location

Real-world data from clinical trials demonstrates site-specific dosing patterns 1:

• Joint bleeds: Mean 28 IU/kg initial dose, 21 IU/kg subsequent doses (most common, 801 infusions studied)
• GI bleeding: Mean 43 IU/kg initial dose, 36 IU/kg subsequent doses—requires higher doses and longer treatment duration (up to 7 days), particularly in VWD type 3 patients 1
• Epistaxis: Mean 25 IU/kg initial dose
• Gynecologic bleeding: Mean 28 IU/kg initial dose

Peri-operative Management

Wilate is NOT FDA-approved for surgical prophylaxis in VWD 1, though clinical trial data supports its use:

• Surgical success rate: 96.7% (29/30 procedures) in prospective trials 2
• Dosing approach: Individualized based on recovery and clearance, targeting VWF:RCo levels of 70-80 IU/dL perioperatively 3
• Administration options: Either continuous infusion or bolus dosing can be used effectively 3

Recent institutional data suggests tailored perioperative dosing based on bleeding risk 4:

• Moderate bleeding risk procedures: Median 29.9 IU/kg loading dose
• High bleeding risk procedures: Median 35.7 IU/kg loading dose
• Orthopaedic/trauma surgery: Highest total perioperative consumption (median 140 IU/kg)

Prophylaxis for Recurrent Bleeding

Long-term prophylaxis with Wilate reduces bleeding by 84-87% compared to on-demand treatment 5:

• Dosing: Mean 27.4 IU/kg at frequency of 1.9 infusions per week (approximately every 3-4 days)
• Efficacy: Annualized bleeding rate decreased from 33.3 bleeds/year on-demand to 5.2 bleeds/year on prophylaxis
• Duration: Studied for 12 months with excellent tolerability 5
• Patient outcomes: 30% had zero bleeding events, 45% had zero spontaneous bleeds during prophylaxis 5

This aligns with 2025 ASH/ISTH/WFH guidelines supporting prophylaxis for patients with severe VWD and frequent recurrent bleeding 6.

Hemophilia A Context

While Wilate is not FDA-indicated for hemophilia A 1, the 2024 ISTH guidelines provide relevant context for plasma-derived FVIII/VWF concentrates:

• Previously untreated patients: Plasma-derived FVIII is conditionally recommended over standard half-life recombinant FVIII for initial prophylaxis (first 50 exposure days) due to potentially lower inhibitor risk 7
• Surgical procedures: Either continuous or bolus infusion of plasma-derived FVIII concentrates is acceptable for major surgery 7

Critical Monitoring Parameters

Laboratory monitoring is highly recommended to ensure adequate factor levels 1:

• Measure VWF:RCo and FVIII activity at suitable intervals
• Adjust dosing based on measured levels, bleeding extent, and clinical condition
• Important caveat: Be aware that continued treatment may cause excessive FVIII accumulation—monitor FVIII levels particularly during prolonged treatment 1

Product-Specific Characteristics

Wilate contains VWF:RCo and FVIII in approximately 1:1 ratio 1. Clinical efficacy data spans over 1,000 bleeding episodes with 84-96% success rates across multiple prospective studies 1, 8, 9. The product demonstrated excellent safety with no inhibitor development, no thromboembolic events, and rare mild adverse reactions 8, 9, 2, 5.

Pediatric Considerations

Dosing in children (≥6 years) does not differ significantly from adults 9, 5:

• Success rate: 87.6% in pediatric bleeding episodes (ages 5-16 years) 1
• Same weight-based dosing applies
• Prophylaxis is effective and well-tolerated in pediatric patients 5